---
title: Statement of the Uterus Commission of the Gynecological Oncology Working Group
  (AGO) on the Use of Primary Chemoimmunotherapy to Treat Patients with Locally Advanced
  or Recurrent Endometrial Cancer
date: '2024-01-17'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38230409/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240117170649&v=2.18.0
source: heidelberg[Affiliation]
description: The publication of two large randomized studies - the ENGOT-EN-6-NSGO/GOG-3031/RUBY
  trial and the NRG-GY018 trial - which investigated combining chemotherapy with immunotherapy
  to treat patients with primary advanced or recurrent endometrial cancer (EC) has
  transformed the clinical study landscape in terms of first-line therapy for affected
  patients and has set a new standard of therapy. In the ENGOT-EN-6-NSGO/GOG-3031/RUBY
  trial, the addition of dostarlimab to standard chemotherapy ...
disable_comments: true
---
The publication of two large randomized studies - the ENGOT-EN-6-NSGO/GOG-3031/RUBY trial and the NRG-GY018 trial - which investigated combining chemotherapy with immunotherapy to treat patients with primary advanced or recurrent endometrial cancer (EC) has transformed the clinical study landscape in terms of first-line therapy for affected patients and has set a new standard of therapy. In the ENGOT-EN-6-NSGO/GOG-3031/RUBY trial, the addition of dostarlimab to standard chemotherapy ...